arrow
N

Nevena Skroza

“sapienza” university of rome
H指数:21
被引数:2,106

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study

中重度 Hidradenitis suppurativa 患者 Secukinumab 的长期疗效:一项多中心队列研究

2026-03-170
PRE
Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index

银屑病严重程度、合并症负担与生物制剂治疗:一项基于Charlson合并症指数的多中心观察性研究

2025-12-311
PRE
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study

银屑病患者中 guselkumab 的长期真实世界有效性与药物生存率:一项为期5年的回顾性研究

2025-09-160
OA
Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy

银屑病患者接受抗白细胞介素-17治疗期间湿疹样皮疹和念珠菌病的预测因素:意大利拉齐奥地区多中心真实世界经验研究

2025-07-013
OA
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study

古塞库单抗在患有感染性合并症、恶性肿瘤或心脏病的银屑病患者中的长期真实世界安全性研究:EARLY研究

2025-04-160
PRE
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio Experience

评估Bimekizumab在不同敏感区域治疗中重度银屑病的疗效:一项为期52周的意大利多中心真实世界拉齐奥经验

2025-04-110
OA
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
2025-04-010
OAAI
OPT-In; Optimized Patient Treatment Outcomes in Plaque Psoriasis: A 3-Year State-Transition Treatment-Sequencing Model in the Italian Setting

选择加入; 斑块状银屑病患者的优化治疗结果: 意大利环境中的3年状态转换治疗排序模型

2024-05-100
OAAI
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

Brodalumab治疗中重度银屑病: 专家Delphi共识声明

2023-05-189
OAAI
External validation of the IHS4-55 in a European antibiotic-treated HS cohort
2023-01-307
OA